^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PT886

    i
    Other names: PT886, PT-886, PT 886
    Associations

    News

    Trials
    Company:
    Phanes Therap
    Drug class:
    CD47 inhibitor, CLDN18.2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3d
    PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (clinicaltrials.gov)
    P1/2, N=135, Recruiting, Phanes Therapeutics | Trial completion date: Apr 2026 --> Apr 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    CLDN18 (Claudin 18)
    |
    HER-2 overexpression • CLDN18.2 expression
    |
    Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • PT886
    9ms
    PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (clinicaltrials.gov)
    P1/2, N=114, Recruiting, Phanes Therapeutics | N=72 --> 114
    Enrollment change
    |
    CLDN18 (Claudin 18)
    |
    HER-2 overexpression • CLDN18.2 expression
    |
    Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • PT886
    10ms
    PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (clinicaltrials.gov)
    P1/2, N=72, Recruiting, Phanes Therapeutics | Phase classification: P1 --> P1/2 | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Nov 2023 --> Dec 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CLDN18 (Claudin 18)
    |
    HER-2 overexpression • CLDN18.2 expression
    |
    gemcitabine • albumin-bound paclitaxel • PT886
    almost2years
    PT886 For Treatment of Patients With Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas (clinicaltrials.gov)
    P1, N=58, Recruiting, Phanes Therapeutics | Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Apr 2024 | Initiation date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2023 --> Nov 2023
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    CLDN18 (Claudin 18)
    |
    HER-2 overexpression
    |
    PT886
    over2years
    PT886 For Treatment of Patients With Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas (clinicaltrials.gov)
    P1, N=58, Not yet recruiting, Phanes Therapeutics
    New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    HER-2 overexpression
    |
    PT886
    over2years
    PT886, an anti-claudin18.2/anti-CD47 bispecific antibody constructed with the PACbodyTM and SPECpairTM technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model (AACR 2022)
    These data support the proof of concept of the PACbody™ and SPECpair™ technology platforms and demonstrate the unique profile of our anti-CD47 arm that’s suitable for the bispecific antibody approach. PT886 is a first-in-class anti-CLDN18.2/anti-CD47 bispecific antibody with native IgG-like structure and phase 1 clinical trial is planned for the first quarter of 2022.
    Preclinical
    |
    CLDN18 (Claudin 18) • CD47 (CD47 Molecule) • CLDN8 (Claudin 8) • SIRPA (Signal Regulatory Protein Alpha)
    |
    CLDN18.2 expression • CLDN18.2 overexpression
    |
    PT886